PSTV Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 09:30):

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases...

Stats
Today's Volume	190.00
Average Volume	30 256.00
Market Cap	6.93M
EPS	$0 ( 2024-04-18 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.380
ATR14	$0.0250 (1.64%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-22	Clowes Howard	Buy	2 250	Stock Option (Right to Buy)
2024-02-22	Lafrance Norman D.	Buy	24 073	Stock Option (Right to Buy)
2024-02-22	Hedrick Marc H	Buy	94 012	Stock Option (Right to Buy)
2024-02-22	Sims Andrew John Hugh Macintyre	Buy	18 933	Stock Option (Right to Buy)
2024-02-22	Lenk Robert P	Buy	2 250	Stock Option (Right to Buy)

INSIDER POWER
99.12
Last 94 transactions
Buy: 2 283 640 \| Sell: 1 020 583

Plus Therapeutics Inc Correlation

10 Most Positive Correlations
VTSI	0.878
EDIT	0.833
ALVR	0.822
MDVL	0.813
LSBK	0.811
SPRO	0.805

10 Most Negative Correlations
BNIXU	-0.904

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Plus Therapeutics Inc Financials

Annual	2023
Revenue:	$4.91M
Gross Profit:	$4.17M (84.84 %)
EPS:	$-4.24

Q4	2023
Revenue:	$1.31M
Gross Profit:	$1.13M (86.14 %)
EPS:	$-0.840

Q3	2023
Revenue:	$1.24M
Gross Profit:	$1.05M (84.84 %)
EPS:	$-1.000

Q2	2023
Revenue:	$1.85M
Gross Profit:	$1.67M (89.86 %)
EPS:	$-0.590

Financial Reports:

No articles found.

Plus Therapeutics Inc

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186 NanoLiposome, a patented radiotherapy that targets central nervous system cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.

Realtime updates for Plus Therapeutics Inc [PSTV]

Upcoming Earnings Alert